Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Patients With Non Muscle Invasive Bladder Cancer

NCT01498172 is registered in ClinicalTrials.gov with Patrice Jichlinski as lead sponsor.

NCT NCT01498172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01498172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Patients With Non Muscle Invasive Bladder Cancer
Lead sponsor
Patrice Jichlinski
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2012
Completion date
Not reported
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer